Business Wire

KURA ONE, Compact Cans of Japanese Sake Featuring Brands From Award-winning Sake Breweries in Japan and Overseas, Is Now Available as a Subscription Service Delivered Worldwide!

Share

KURA ONE meticulously selects sake from brands of award-winning sake breweries in Japan and overseas and repackages them in compact and easy-to-handle 180ml/196g aluminum cans, while maintaining the quality of the sake. On January 31, the first canned sake subscription service in the world that delivers sake, along with stories about enjoying sake, directly to customers via subscription in more than 100 countries has launched online ordering. As a result of the service's introduction in numerous media sources, it has been attracting attention in Japan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223006067/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sake breweries from different regions also participated in the press conference. (Photo: Business Wire)

“KURA ONE Sales Commemorative Special Edition,” which is a complete set of all 21 brands to be delivered from January to June 2023, and the Assortment Box with special sake containers featuring Japanese craftsmanship are very popular.

Also, KURA ONE's brand movie "KURA ONE TRIP." which introduces sake breweries and their regions is now online. On February 28 (Tue.), KURA ONE begins accepting applications worldwide for BtoB partners (restaurants, sake retailers, etc.) who can place orders for as little as 30 cans.

Video of press conference in Tokyo (English version): https://www.youtube.com/watch?v=aTTeue_Y2Ig
KURA ONE TRIP.: https://sake.japanpage.jp/en/pages/kuraone_movies

[Six new Collections. Now shipping to 100 countries around the world!]

  1. “KURA ONE STORY. Subscription”: 3-4 cans of brands from domestic and international award-winning sake breweries delivered each month.
    Price: 3,600 yen (tax not included) per month, limited to the first 2,000 slots
  2. “KURA ONE Sales Commemorative Special Edition”: a special complete set of 21 cans of brands from award-winning sake breweries in Japan and overseas. Price: 23,000 yen (without tax) and limited to the first 500 sets.
  3. "KURA ONE Glass Sake Cup Box": includes 4 types of sake glasses of Kimoto Glassware used in famous restaurants, and 2 cans of KURA ONE. Price: 16,800 yen (without tax) and limited to the first 100 sets.
  4. "KURA ONE Traditional Craft Sake Cup Box": includes 3 types of traditional craft sake vessels such as Ceramic (Shigaraki) and Porcelain (Kutani) and 2 cans of KURA ONE. Price: 7,600 yen (without tax) and limited to the first 100 sets.
  5. "KURA ONE Temperature Sensitive Sake Cups Box": includes 2 mysterious sake vessels whose cherry blossom color changes depending on the sake temperature, and 2 cans of KURA ONE. Price: 5,400 yen (without tax) and limited to the first 100 sets.
  6. "KURA ONE Gacha Box": an experimental box for starters. You will enjoy 2 cans of KURA ONE after they arrive. Price: 1,700 yen (without tax)
  • Shipping fees and taxes not included.

Click here to purchase (on the official website):
English: https://sake.japanpage.jp/en/pages/kuraone
French: https://sake.japanpage.jp/fr/pages/kuraone
Traditional Chinese: https://sake.japanpage.jp/zh-tw/pages/kuraone
Simplified Chinese: https://sake.japanpage.jp/zh-cn/pages/kuraone
Japanese: https://sake.japanpage.jp/pages/kuraone

[Now accepting applications for BtoB partners worldwide]

We are seeking BtoB sales partners to create new sake drinking scenes that integrate with the lifestyles of consumers in various parts of the world.

KURA ONE places importance on its target users and sales method. We will interview each company to make decisions based on the proposal content and their enthusiasm for the project, rather than on a first-come, first-served basis. This is not an exclusive offer for one company in one country. Currently, we have begun to conclude business negotiations with restaurants and sake retailers in Asia, Europe, and the United States.

Overview of BtoB sales partnerships / Transaction details / Privileges / How to apply (5 languages): https://sake.japanpage.jp/en/pages/kuraone_btob

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

KURA ONE
Public Relations: Tomoko Takiguchi
+81-80-8422-5844
info@greencreate.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye